Samsara BioCapital and Enavate Sciences led a $75m Series B round in Normunity.

Venture capital firms Samsara BioCapital and Enavate Sciences, led a $75m Series B round in Normunity, a biotechnology company, with participation from Regeneron Ventures, Pfizer Ventures and YK Bioventures, Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. “We are delighted to secure this financing from such an experienced and well-respected syndicate of life sciences investors. Their support will enable Normunity to continue our strong momentum and advance our lead drug program NRM-823 into the clinic this year and explore other modalities with this exciting tumor specific target. With our proprietary target discovery process, we will continue to build our pipeline around novel targets, with new biological insights that could translate into life-changing medicines for cancer patients,” Rachel Humphrey, MD, Normunity Founding Chief Executive Officer.